Clinical Report: Migaldendranib Demonstrates Efficacy in DME and nAMD
Overview
Migaldendranib significantly reduced the need for intravitreal injections in patients with diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) during a phase 2 trial, showing improvements in visual acuity (average gain of 6.1 ETDRS letters) and retinal structure (reduction in central subfield thickness) without serious adverse events.
Background
Diabetic macular edema and neovascular age-related macular degeneration are leading causes of vision loss. Current treatment strategies primarily rely on intravitreal anti-VEGF therapies, which can be burdensome due to frequent injections. New therapies that reduce injection frequency while maintaining efficacy are essential for improving patient outcomes.
Data Highlights
| Parameter | Baseline | Post-Treatment | Reduction |
|---|---|---|---|
| Annualized Injection Rate (Study Eyes) | 8.4 | 1.6 | ~80% |
| Annualized Injection Rate (Fellow Eyes) | 8.3 | 0.9 | ~90% |
| Visual Acuity Gain (ETDRS Letters) | - | 6.1 | - |
| Central Subfield Thickness | - | Reduced (specific measurement needed) | - |
Key Findings
- Migaldendranib reduced the need for intravitreal injections by nearly 80% in study eyes and 90% in fellow eyes.
- Participants gained an average of 6.1 ETDRS letters in visual acuity for DME eyes, indicating significant improvement.
- Reductions in central subfield thickness were observed, indicating improvements in retinal structure (specific measurements needed).
- No serious treatment-related systemic or ocular adverse events were reported.
- The drug allows for monthly, at-home subcutaneous administration, potentially reducing treatment burden.
Clinical Implications
The findings suggest that migaldendranib may offer a viable alternative to current intravitreal therapies, potentially enhancing patient adherence and comfort. Further studies are necessary to confirm these results, assess long-term safety and efficacy, and address regulatory considerations.
Conclusion
Migaldendranib shows promise in reducing treatment burden for patients with DME and nAMD, warranting further investigation to establish its role in clinical practice.
References
- Ashvattha Therapeutics, Ashvattha Therapeutics, 2025 -- Positive Topline 40-Week Phase 2 Results for Migaldendranib
- Michael A. Singer, MD, Retinal Physician, 2025 -- Migaldendranib May Move the Needle in AMD, DME
- Retinal Physician, Retinal Physician, 2009 -- RPS: From the Podium to the Practice
- Retinal Physician, Retinal Physician, 2023 -- Clinical Trial Update July/August 2023
- Medthority, AAO 2025 -- Age-Related Macular Degeneration Guidelines
- retinal physician — Clinical Trial Update January/February 2025
- AAO 2025: Age-Related Macular Degeneration Guidelines - Medthority
- Intravitreal Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: Ninety-Six-Week Results from the Randomized Phase 3 PULSAR Trial - ScienceDirect
- Ashvattha Therapeutics Announces Positive Topline 40-Week Phase 2 Results for Migaldendranib in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration – Ashvattha Therapeutics
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.